Literature DB >> 22328068

Vitamin D and vascular disease: the current and future status of vitamin D therapy in hypertension and kidney disease.

Anand Vaidya1, John P Forman.   

Abstract

Over the past decade, vitamin D has generated considerable interest as potentially having important effects on the vasculature and the kidney. Animal and human data indicate that vitamin D suppresses the activity of the renin-angiotensin system and improves endothelial function. Observational studies in humans suggest that low 25-hydroxyvitamin D (25[OH]D) levels are associated with a higher risk of hypertension. However, findings from randomized trials of vitamin D supplementation (with cholecalciferol or ergocalciferol) to lower blood pressure are inconsistent, possibly stemming from variability in study population, sample size, vitamin D dose, and duration. Supplementation with activated vitamin D (i.e., 1,25-dihydroxyvitamin D or analogues) in patients with chronic kidney disease reduces urine albumin excretion, an important biomarker for future decline in renal function. These studies are reviewed, with special emphasis on recent findings. Definitive studies are warranted to elucidate the effects of vitamin D supplementation on mechanisms of hypertension and kidney disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22328068      PMCID: PMC4281261          DOI: 10.1007/s11906-012-0248-9

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  94 in total

Review 1.  Vitamin D and hypertension: current evidence and future directions.

Authors:  Anand Vaidya; John P Forman
Journal:  Hypertension       Date:  2010-10-11       Impact factor: 10.190

2.  Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans.

Authors:  John P Forman; Jonathan S Williams; Naomi D L Fisher
Journal:  Hypertension       Date:  2010-03-29       Impact factor: 10.190

3.  Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.

Authors:  Dick de Zeeuw; Rajiv Agarwal; Michael Amdahl; Paul Audhya; Daniel Coyne; Tushar Garimella; Hans-Henrik Parving; Yili Pritchett; Giuseppe Remuzzi; Eberhard Ritz; Dennis Andress
Journal:  Lancet       Date:  2010-11-06       Impact factor: 79.321

4.  No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year.

Authors:  R Jorde; M Sneve; P Torjesen; Y Figenschau
Journal:  J Intern Med       Date:  2009-10-19       Impact factor: 8.989

5.  Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system.

Authors:  Yan Zhang; Juan Kong; Dilip K Deb; Anthony Chang; Yan Chun Li
Journal:  J Am Soc Nephrol       Date:  2010-04-08       Impact factor: 10.121

6.  Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes.

Authors:  Dilip K Deb; Tao Sun; Kari E Wong; Zhongyi Zhang; Gang Ning; Yan Zhang; Juan Kong; Helen Shi; Anthony Chang; Yan Chun Li
Journal:  Kidney Int       Date:  2010-02-24       Impact factor: 10.612

7.  Association of resistin and adiponectin with different clinical blood pressure phenotypes.

Authors:  C Thomopoulos; M Daskalaki; O Papazachou; N Rodolakis; A Bratsas; D P Papadopoulos; M V Papavasileiou; D Perrea; T Makris
Journal:  J Hum Hypertens       Date:  2010-03-04       Impact factor: 3.012

Review 8.  Systematic review: Vitamin D and cardiometabolic outcomes.

Authors:  Anastassios G Pittas; Mei Chung; Thomas Trikalinos; Joanna Mitri; Michael Brendel; Kamal Patel; Alice H Lichtenstein; Joseph Lau; Ethan M Balk
Journal:  Ann Intern Med       Date:  2010-03-02       Impact factor: 25.391

9.  Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study.

Authors:  Andreas Tomaschitz; Stefan Pilz; Eberhard Ritz; Tanja Grammer; Christiane Drechsler; Bernhard O Boehm; Winfried März
Journal:  Clin Chim Acta       Date:  2010-06-01       Impact factor: 3.786

10.  Serum 25-hydroxyvitamin D levels are strongly related to systolic blood pressure but do not predict future hypertension.

Authors:  Rolf Jorde; Yngve Figenschau; Nina Emaus; Moira Hutchinson; Guri Grimnes
Journal:  Hypertension       Date:  2010-01-11       Impact factor: 10.190

View more
  16 in total

Review 1.  Nutraceuticals and Blood Pressure Control: Results from Clinical Trials and Meta-Analyses.

Authors:  Arrigo F G Cicero; Alessandro Colletti
Journal:  High Blood Press Cardiovasc Prev       Date:  2015-03-19

Review 2.  The renin-angiotensin-aldosterone system and calcium-regulatory hormones.

Authors:  A Vaidya; J M Brown; J S Williams
Journal:  J Hum Hypertens       Date:  2015-01-29       Impact factor: 3.012

Review 3.  Evidence of clinically relevant efficacy for dietary supplements and nutraceuticals.

Authors:  Arrigo F G Cicero; Claudio Borghi
Journal:  Curr Hypertens Rep       Date:  2013-06       Impact factor: 5.369

4.  Low 25-hydroxyvitamin D levels and cognitive impairment in hemodialysis patients.

Authors:  Kamran Shaffi; Hocine Tighiouart; Tammy Scott; Kristina Lou; David Drew; Daniel Weiner; Mark Sarnak
Journal:  Clin J Am Soc Nephrol       Date:  2013-02-28       Impact factor: 8.237

Review 5.  Interactions between adrenal-regulatory and calcium-regulatory hormones in human health.

Authors:  Jenifer M Brown; Anand Vaidya
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-06       Impact factor: 3.243

6.  The problems of vitamin d insufficiency in older people.

Authors:  Barbara J Boucher
Journal:  Aging Dis       Date:  2012-06-06       Impact factor: 6.745

7.  Effect of vitamin D supplementation versus placebo on essential hypertension in patients with vitamin D deficiency: a double-blind randomized clinical trial.

Authors:  Vida Sheikh; Azadeh Mozaianimonfared; Mohsen Gharakhani; Jalal Poorolajal
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-09-20       Impact factor: 3.738

8.  Vitamin D supplementation for the prevention of type 2 diabetes in overweight adults: study protocol for a randomized controlled trial.

Authors:  Barbora de Courten; Aya Mousa; Negar Naderpoor; Helena Teede; Maximilian P J de Courten; Robert Scragg
Journal:  Trials       Date:  2015-08-07       Impact factor: 2.279

9.  Evaluating hormonal mechanisms of vitamin D receptor agonist therapy in diabetic kidney disease: the VALIDATE-D study.

Authors:  Jenifer M Brown; Kristina Secinaro; Jonathan S Williams; Anand Vaidya
Journal:  BMC Endocr Disord       Date:  2013-08-23       Impact factor: 2.763

10.  Plasma 25-hydroxyvitamin D and risk of premenstrual syndrome in a prospective cohort study.

Authors:  Elizabeth R Bertone-Johnson; Susan E Hankinson; Nancy G Forger; Sally I Powers; Walter C Willett; Susan R Johnson; JoAnn E Manson
Journal:  BMC Womens Health       Date:  2014-04-12       Impact factor: 2.809

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.